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Conventional dendritic cells (cDCs) are versatile activators of immune responses that 
develop as part of the myeloid lineage downstream of hematopoietic stem cells. We 
have recently shown that in mice precursors of cDCs, but not of other leukocytes, are 
marked by expression of DNGR-1/CLEC9A. To genetically deplete DNGR-1-expressing 
cDC precursors and their progeny, we crossed Clec9a-Cre mice to Rosa-lox-STOP-lox-
diphtheria toxin (DTA) mice. These mice develop signs of age-dependent myeloprolif-
erative disease, as has been observed in other DC-deficient mouse models. However, 
despite efficient depletion of cDC progenitors in these mice, cells with phenotypic char-
acteristics of cDCs populate the spleen. These cells are functionally and transcriptionally 
similar to cDCs in wild type control mice but show somatic rearrangements of Ig-heavy 
chain genes, characteristic of lymphoid origin cells. Our studies reveal a previously unap-
preciated developmental heterogeneity of cDCs and suggest that the lymphoid lineage 
can generate cells with features of cDCs when myeloid cDC progenitors are impaired.
Keywords: dendritic cell, development, clec9a/Dngr-1, Dc depletion, myelopoiesis, lymphopoiesis, fate 
mapping
inTrODUcTiOn
Conventional dendritic cells (cDCs) are remarkable activators of adaptive immune responses with a 
superior capacity to capture, process, and present antigens to T cells (1–4). Through the production 
of cytokines, cDCs further direct effector responses and play essential roles in immune homeostasis 
and innate immunity (5–10). This versatility of cDCs in immune responses is regulated in part 
through the functional specialization of cDC subpopulations. cDCs exist as two main developmen-
tally distinct subsets that are found across lymphoid and non-lymphoid organs. cDC1 requires the 
transcription factors Batf3, IRF8, and ID2 for their development and are marked by expression of 
XCR1 and DNGR-1 (a.k.a. CLEC9A) across tissues and species (1, 11, 12). They are exceptional acti-
vators of CD8 T cells owing to their superior capacity to take up dead cells and cross-present antigens 
(1–4). Through the production of IL-12, cDC1 promotes type-I immune responses hallmarked by 
expression of Th1 cytokines (1, 5). In contrast, the differentiation and function of the cDC2 subset 
is controlled by the transcription factors IRF4, KLF4, RelB, and ZEB2 (1, 11–14), although ZEB2 
may predominantly control cDC2 differentiation in inflammatory conditions (15). Phenotypically 
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cDC2 can be distinguished from cDC1 by expression of CD11b, 
CD172a, and CLEC4A4 (DCIR2), as well as expression of IRF4 
and concomitant lack of IRF8 (1, 11, 12, 16). cDC2 appears to 
play a more prominent role in CD4 T-cell activation and the 
promotion of Th2 and Th17 responses, particularly at mucosal 
surfaces (17, 18).
Although the existence of cDCs as independent cell type 
has been a matter of intense debate, lineage tracing and other 
studies in mice have established that cDCs develop as distinct 
hematopoietic cell lineage (12, 19, 20). Single-cell analyses have 
recently suggested that myeloid lineage decisions take place early 
in hematopoiesis but the production of lymphoid and myeloid 
lineages is thought to branch after the lymphoid-primed multi-
potent progenitor (LMPP) stage (20–24). Downstream of LMPP, 
in a stepwise differentiation process, common myeloid progeni-
tors give rise to a lineage (lin) negative CD115+CD117hiCD135+ 
fraction of bone marrow that generates monocytes, plasma-
cytoid DCs (pDCs), and cDCs and has therefore been termed 
macrophage and DC progenitor (MDP) (25, 26). Whether MDPs 
are a true bi-potent developmental intermediate for cDCs/pDCs 
and monocytes is controversial (27). MDPs further give rise 
to common monocyte progenitors that exclusively generate 
monocytes (28) and a lin−CD115+CD117lowCD135+ fraction of 
cells termed common DC progenitors (CDP) that lose monocyte 
potential but generate cDCs and pDCs (29, 30). Within CDPs the 
expression of the C-type lectin receptor DNGR-1 (encoded by 
the Clec9a gene) distinguishes cells with exclusive cDC potential 
(19). CDPs further differentiate into pre-cDCs, which also express 
DNGR-1 (19) and travel via blood to peripheral organs, where 
their terminal differentiation into cDC1 and cDC2 takes place in 
response to environmental cues (31–33). Some pre-cDCs exist 
as pre-committed subsets that can be already distinguished in 
bone marrow based on the expression of specific surface markers 
and transcription factors (32, 34, 35). The developmental steps of 
cDC differentiation appear conserved, as equivalent progenitors 
and transcriptional requirements for cDC differentiation have 
been identified in humans (12, 36–40).
By crossing mice expressing Cre recombinase (Cre) under 
the control of the endogenous Clec9a promoter to Rosa26-
lox-STOP-lox-yellow fluorescent protein (YFP) reporter mice, 
we were able to demonstrate that Clec9a expression history 
faithfully traces the cDC lineage, including the main cDC1 and 
cDC2 subsets, but no other myeloid and lymphoid lineages in 
steady state as well as during inflammation (19). In this model, 
any cell-expressing Cre becomes irreversibly labeled with YFP, 
thereby allowing us to trace DNGR-1-expressing CDP and pre-
cDC irrespective of continuous DNGR-1 expression (19). One 
exception to faithful tracing of the cDC lineage is pDCs, which do 
not arise from DNGR-1-expressing cDC progenitors but express 
low levels of DNGR-1 in their differentiated form (19). In pDCs 
Clec9a expression history, therefore, is not necessarily a measure 
of cell origin (19). The same applies to cDC1, which express high 
levels of DNGR-1 and could become labeled with YFP because 
they express Cre in their differentiated form (19). However, cDC1 
are CDP-derived (1, 11) and arise from DNGR-1-expressing cDC 
progenitors upon adoptive transfer, confirming their classifica-
tion as cDCs (19). Despite these limitations, Clec9a-Cre mice 
offer a powerful means to identify cDCs as descendants from 
Clec9a-expressing cDC progenitors and to trace the cDC line-
age, particularly the cDC2 subtype, which lacks DNGR-1 in its 
differentiated form.
Although we have reached a consensus that cDCs arise as part 
of the myeloid lineage, several studies have suggested a lymphoid 
path to cDC development. Purified lymphoid progenitors can 
differentiate into cells resembling cDC1 and cDC2 after adoptive 
transfer and in vitro (41–47). This process appears to be driven 
by the same lineage promoting transcription factors that control 
cDC development from myeloid progenitors, such as IRF8 (46, 
48). Additionally, B-cell receptor gene rearrangements at the IgH 
locus, indicative of a lymphoid past, can be found in popula-
tions of thymic cDCs, some splenic cDC1, and pDCs (49–52). 
Nevertheless, fate-mapping studies in steady-state mice have 
excluded a prominent contribution of lymphoid progenitors to 
the steady-state cDC pool (53, 54) and have confirmed a binary 
branching of lymphoid and myeloid lineages downstream of 
hematopoietic stem cells (21). However, whether lymphoid 
progenitors can serve as an alternative path to DC poiesis in 
conditions of inflammation or when myeloid cDC progenitors 
are absent has not been investigated. Because cDCs generated 
in vitro from purified human lymphoid or myeloid progenitors are 
indistinguishable by gene expression analysis (42), addressing this 
question requires faithful ontogeny-based fate-mapping models.
Here, we investigated cDC development in mice in conditions 
in which cDC progenitors are impaired. We crossed Clec9a-Cre 
mice to Rosa26-lox-STOP-lox-diphtheria toxin (DTA) reporter 
mice (55) (Clec9aCreRosaDTA) to constitutively deplete Clec9a-
expressing cDC progenitors and their progeny. We found that 
Clec9aCreRosaDTA mice lack cDC progenitors and cDC1 but not 
cDC2. We show that in the absence of cDC progenitors, cells 
with features of cDC2 arise via an alternative developmental 
path. These cells show similarities to bona fide cDC2 in terms 
of transcriptional profile and inflammatory cytokine production 
but exhibit evidence of Ig receptor rearrangements, indicating a 
lymphoid origin. Thus, our data suggest a previously unrecog-
nized role for lymphoid progenitors as an alternative source of 
cDC2, when the conventional myeloid path of cDC development 
is blocked.
MaTerials anD MeThODs
Mice
Clec9a-Cre (19), Rosa26-lox-STOP-lox-EYFP (56), Rosa26-lox-
STOP-lox-DTA (55), Rosa26-lox-STOP-lox-DTR (57), C57BL/6J, 
and B6.SJL mice were bred at Cancer Research UK, at ENVIGO 
or the Biomedical Center in specific pathogen-free conditions. All 
animal experiments were performed in accordance with national 
and institutional guidelines for animal care and approved by the 
Francis Crick Institute Animal Ethics Committee, the UK Home 
Office, or the Regierung of Oberbayern.
cell isolation
Spleen and lymph nodes were cut into small pieces and digested 
with Collagenase IV (200  U/mL; Worthington) and DNase I 
(0.2  mg/mL Roche) in RPMI for 30  min at 37°C. Cells were 
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strained through 70-µm cell strainers (BD Biosciences), washed 
with FACS buffer [PBS, 1% fetal calf serum (FCS), 2.5-mM EDTA, 
0.02% sodium azide] and incubated for 2 min in red blood cell lysis 
buffer (Sigma). Cells were then washed and resuspended in FACS 
buffer. Bone marrow was isolated by flushing one femur with 
FACS buffer onto a cell strainer. Erythrocytes were lysed as above. 
Colonic single-cell suspensions were prepared as published (19).
cell culture
CD11c+ cells from spleen were enriched by positive selection 
using magnetic beads and LS-columns (Miltenyi), cultured 
in complete RPMI (10% FCS, penicillin/streptomycin, non-
essential amino acids, sodium pyruvate, L-glutamine, 0.025-mM 
β-mercaptoethanol), and stimulated with LPS (100  ng/mL) or 
CpG (0.5 µg/mL) for 2 h before addition of brefeldin A (5 µg/
mL) for an additional 4 h.
elisa
FLT3L and G-CSF were measured with DuoSet mFLT3L (DY427) 
and Quantikine® ELISA kits (both R&D Systems) according to 
the manufacturer’s recommendations. Other cytokines were 
measured by Legendplex (BioLegend).
Flow cytometry
Data were collected on a LSR Fortessa (BD Biosciences) and 
analyzed with FlowJo software (Tree Star, Inc.). Cell sorting was 
performed on an Aria III Fusion (BD Biosciences). Antibodies 
used in this study can be found in Table S2 in Supplementary 
Material. For intracellular cytokine staining cells were fixed with 
2% paraformaldehyde (15 min, room temperature), then washed 
in FACS buffer with 0.05% saponin and stained in 0.5% saponin. 
IRF8 and IRF4 were stained in Foxp3 transcription factor staining 
set (eBioscience-00-5523-00) and Zbtb46 in transcription factor 
buffer from BDBioscience-562574. Dead cells were identified 
with Dapi or live/dead fixable violet (Invitrogen) or zombie UV 
dye (Biolegend).
Microarray analysis
CD11c+ cells were enriched using magnetic beads and LS 
columns (Miltenyi Biotec). Cells were then sorted as CD11c+ 
MHCII+CD11b+CD24−CD64−Gr-1− cells from Clec9acre/cre 
RosaDTA mice or as YFP+CD11c+MHCII+CD11b+CD24−CD64− 
Gr-1− cells from Clec9acre/creRosaYFP mice. Total RNA was isolated 
using Qiagen RNeasy Micro Kit and prepared for hybridization 
on Affymetrix Mouse Gene 1.0 ST Arrays. We processed microar-
ray data with R/bioconductor (R version 3.4.2) using the annota-
tion package “mogene10sttranscriptcluster.db” version 8.7.0. The 
Robust Multichip Average (RMA) algorithm was used to extract 
raw expression values (library “oligo,” version 1.42.0 and “pd.
mogene.1.0.st.v1” version 3.14.1). We subsequently removed 
probe sets with zero variance and kept the ones with a median 
log2 expression level higher than 4.5 in at least one condition. 
Many-to-one probe-sets-to-gene relationships were resolved 
by retaining per gene only the probe set with the highest inter-
quartile range of expression levels across the samples. External 
data were merged and batch corrected using ComBat (library 
“sva,” version 3.26.0). Principle component analysis (PCA) was 
performed on 50% of the genes defined by highest variance across 
all samples. Heatmaps were generated using function pheatmap 
(library pheatmap, version 1.0.8) including gene-based scaling 
and clustering.
DJ-rearrangement Polymerase chain 
reaction (Pcr)
Genomic DNA was extracted by phenol chloroform extraction 
and 20-ng DNA were used per reaction. PCR for the IgH locus 
(Dfl16 and Dsp2 D gene families) (58) was split in two reactions 
for Germline (J3 & Mu0) and DJ-rearrangement (DH L & J3).
DHL-GGAATTCG(AorC)TTTTTGT(CorG)AAGGGA 
TCTACTACTGTG;
Mu0-CCGCATGCCAAGGCTAGCCTGAAAGATTACC; 
J3-GTCTAGATTCTCACAAGAGTCCGATAGACCCTGG. 
IgH DJ-rearrangements for the DHQ52 element were assessed 
by sequential PCRs with the following primers:
PCR-1: DHQ52-1-CACAGAGAATTCTCCATAGTTGATAGC 
T C A G ; D H Q 5 2 - 2 G C C T C A G A AT T C C T G T G G T C 
TCTGACTGGT; PCR-2: JH4-1-AGGCTCTGAGATCCCTAG 
ACAG; JH4-2- GGGTCTAGACTCTCAGCCGGCTCCCTC 
AGGG as previously described (51).
Diphtheria Toxin (DT)-Mediated cell 
ablation
Mice were injected intraperitoneally with 25 ng per gram body 
weight DT (SIGMA). Spleens were analyzed 24 h later.
statistical analysis
Statistical testing was performed using two-sided, unpaired 
Welch t-tests in GraphPad Prism 6 software (GraphPad, La Jolla, 
CA, USA). A p < 0.05 was considered significant.
resUlTs
Clec9aCre/CreRosaDTA Mice Develop 
Myeloproliferative Disease
To generate mice lacking progeny derived from cDC-restricted 
progenitors, we crossed Clec9a-Cre mice to Rosa26-lox-STOP-
lox-DTA reporter mice to induce apoptotic cell death in Cre-
expressing cells and their progeny (55). We have previously 
shown that the penetrance of Cre-mediated recombination is 
increased in homozygous Clec9a-Cre mice without affecting 
specificity (19). For most experiments, we therefore generated 
mice homozygous for the Clec9a-Cre locus that were either 
heterozygous or homozygous for the Rosa26-lox-STOP-lox-
DTA allele (henceforth referred to as Clec9aCre/CreRosaDTA 
mice). Clec9aCre/CreRosaDTA mice were born at Mendelian ratio 
and developed normally (not shown). With age, spleens from 
Clec9aCre/CreRosaDTA mice appeared larger (not shown) and 
exhibited significantly increased cellularity compared to spleens 
from littermate controls (Clec9a+/+RosaDTA or Clec9aCreRosa+/+ 
mice, henceforth referred to as controls, Figure 1A). Despite 
prominent splenomegaly in mice 10 weeks or older, no differ-
ence in bone-marrow cellularity was observed (Figure  1A). 
FigUre 1 | Clec9acre/creRosaDTA mice showing signs of age-dependent myeloproliferation. (a) The total number of leukocytes per spleen and femur from control and 
Clec9acre/creRosaDTA mice of the indicated ages is shown. (B,c) Ly-6C+CD11b+ cells were identified by flow cytometry in spleen from control and Clec9acre/creRosaDTA 
mice. (B) Representative gating strategy of Ly-6C+CD11b+ cells in 10-week-old mice. Plots are gated on DAPI− live cells. (c) Frequency and total counts of 
Ly-6C+CD11b+ cells in mice of the indicated ages and genotypes. (D) Serum was collected from control and Clec9acre/creRosaDTA mice at 6 and 14–17 weeks of age 
and the concentrations of FLT3L were determined by ELISA. Each symbol represents one mouse. ns, not significant; * p < 0.05, ** p < 0.001, and *** p < 0.0001.
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DC deficiency is associated with myeloproliferation leading 
to systemic neutrophilia and monocytosis (59–62). In 5-week-
old mice, we observed no differences in the frequency and 
number of Ly-6C+CD11b+ myeloid cells but in mice 10 weeks 
or older Ly-6C+CD11b+ cells were significantly increased 
(Figures 1B,C). This age-dependent increase in Ly-6C+CD11b+ 
cells encompassed both neutrophils and monocytes, whereas 
red pulp macrophages were not affected (Figures S1A–C in 
Supplementary Material). Myeloproliferation in DC-deficient 
mice is thought to be secondary to dysregulation of growth 
factors, such as FLT3L, G-CSF, or GM-CSF (59, 61). Clec9aCre/Cre 
RosaDTA mice displayed increased serum levels of FLT3L, with 
a slight increase evident even before the onset of overt spleno-
megaly in 6-week-old mice (Figure 1D). Systemic levels of other 
cytokines implicated in neutrophil and monocyte homeostasis 
were unaffected (Figure S1D in Supplementary Material). Of note, 
we could not detect GM-CSF in serum of control or Clec9aCre/Cre 
RosaDTA mice (unpublished observation). Therefore, Clec9aCre/Cre 
RosaDTA mice develop splenomegaly and exhibit increased 
levels of FLT3L, reminiscent of the myeloproliferative disease 
reported in other cDC-deficient animal models (59, 61–63).
loss of cDc1 but not cDc2 in Clec9aCre/Cre 
RosaDTA Mice
To analyze the efficiency of cDC depletion in Clec9aCre/CreRosaDTA 
mice, we focused on steady-state spleen, where cDCs can reliably 
be identified as CD11c+MHCII+ cells and the two main cDC1 and 
cDC2 subsets can be distinguished as CD24+ and CD11b+ cells, 
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respectively (Figure 2A) (12). At 10 weeks of age Clec9aCre/CreRosaDTA 
mice showed a twofold reduction in the frequency of splenic cDCs 
compared to controls. Due to the increased organ cellularity, 
however, there was no effect on the absolute number of splenic 
CD11c+MHCII+ cells (Figures  2A,B). The same was observed 
in older Clec9aCre/CreRosaDTA mice (14–17  weeks; Figure  2B). In 
5-week-old mice that do not exhibit increased spleen cellularity, 
a reduction of splenic CD11c+MHCII+ cells was apparent in cell 
counts (Figure 2B), yet cell depletion was surprisingly inefficient 
(about 3.5-fold). When we further separated CD11c+MHCII+ 
cells into cDC1 and cDC2 using the surface markers CD24 and 
CD11b (Figure 2A), we found that cDC1 were completely depleted 
in spleens from Clec9aCre/CreRosaDTA mice at all ages examined 
(Figure 2C and unpublished observations). In contrast, CD11b+ 
cDC2 showed a significant but small reduction (Figure  2C) 
only in 5-week-old Clec9aCre/CreRosaDTA mice and their frequency 
and absolute number was not reduced in mice 10 weeks or older 
(Figure 2C). This could be seen in other lymphoid organs, as well 
as in mice heterozygous for Cre expression, as the lymph nodes of 
Clec9a+/CreRosaDTA mice also lacked cDC1 but not resident cDC2 
or migratory CD103+CD11b+ and CD103- CD11b+ cDC2 (Figure 
S2F in Supplementary Material). Finally, these findings could be 
extended to non-lymphoid organs as cDC1 but not CD103+CD11b+ 
or CD103− CD11b+ cDC2 were absent from colon of Clec9aCre/Cre 
RosaDTA mice (Figure S2G in Supplementary Material).
The lack of cDC2 depletion was surprising, as this population 
shows near complete fluorescent reporter labeling in Clec9aCre/Cre 
RosaYFP mice (19) and can be depleted with DT in Clec9a-Cre 
mice crossed to Rosa26-lox-STOP-lox-diphtheria toxin receptor 
mice (DTR; Clec9aCre/CreRosaDTR) (64). We confirmed that a single 
injection of DT was sufficient to efficiently deplete pre-cDCs, 
cDC1, and cDC2 in Clec9aCre/CreRosaDTR mice (Figures  2D,E; 
Figures S2A,B in Supplementary Material). Of note, 24 h after 
DT injection no increase in splenic neutrophils or monocytes was 
observed (Figure S2C in Supplementary Material), suggesting 
that Clec9aCre/CreRosaDTR mice do not develop acute monocytosis 
and neutrophilia (62). Therefore, Clec9a-Cre mice serve as an 
efficient model to transiently deplete cDC1 and cDC2 when 
crossed to RosaDTR mice (64) but depletion of cDC2 is not seen 
when crossed to RosaDTA mice.
Fully differentiated pDCs express low levels of DNGR-1 
although they do not arise from DNGR-1-expressing CDPs (19). 
Splenic pDC numbers were not altered in Clec9aCre/CreRosaDTA mice 
(Figure S2D in Supplementary Material). However, pDCs that 
developed in Clec9a+/CreRosaDTA mice almost completely lacked 
DNGR-1 (Figure S2E in Supplementary Material). These data 
suggest that DNGR-1-expressing pDCs are depleted and replaced 
with DNGR-1 negative pDCs. We conclude that constitutive 
depletion of DNGR-1-expressing cells in Clec9aCre/CreRosaDTA adult 
mice leads to a complete loss of cDC1 but not cDC2 or pDCs.
efficient Depletion of Pre-cDcs in Bone 
Marrow and spleen of Clec9aCre/CreRosaDTA 
Mice
We next investigated whether cDC progenitors were 
depleted in Clec9aCre/CreRosaDTA mice. As expected, Clec9aCre/Cre 
RosaDTA mice showed no reduction in MDPs lin− 
CD11c−CD115+CD135+CD117hi compared to control mice 
(Figures  3A,B). In contrast, CDPs (lin−CD11c−CD115+CD135+
CD117low/−) were significantly reduced in Clec9aCre/CreRosaDTA mice 
(Figures 3A,B). High serum levels of FLT3L in Clec9aCre/CreRosaDTA 
mice could have led to downregulation of CD135 in MDPs or 
CDPs, causing them to be missed in our gating. This was not 
the case because bone marrow lin−CD11c−CD115+CD117hi and 
lin−CD11c−CD115+CD117low/− cells from control and Clec9aCre/Cre 
RosaDTA mice expressed similar levels of CD135 (Figure  3C). 
Pre-cDCs, identified as lin−CD11c+CD135+CD172alow cells, 
were also nearly absent in bone marrow of Clec9aCre/CreRosaDTA 
mice when compared to controls (Figures  3A,B) and this was 
true when pre-cDC were also identified irrespective of the 
CD135 marker as the lin−CD11c+ fraction of bone marrow 
(Figure S3A in Supplementary Material). Similarly, in spleen, 
lin−CD11c+CD43+CD135+CD172alow pre-cDCs were virtu-
ally absent in Clec9aCre/CreRosaDTA mice, as well as heterozygous 
Clec9a+/CreRosaDTA mice (Figures  3D,E; Figure S3C in 
Supplementary Material). Although CD43+CD135− cells were 
found in the splenic pre-cDC gate, those cells expressed reduced 
levels of CD11c, indicating that they were contaminants rather 
than bona fide pre-cDCs (Figures  3D–F; Figures S3B,C in 
Supplementary Material). A more efficient depletion of pre-cDCs 
compared with CDPs is to be expected because Cre-mediated DNA 
rearrangement in pre-cDCs is higher than in CDPs, reflecting the 
developmental hierarchy of DNGR-1 expression in rapidly cycling 
progenitors (19). Thus, our data indicate efficient depletion of cDC 
progenitors in bone marrow and spleen of Clec9aCre/CreRosaDTA mice 
and suggest that cells resembling cDC2 in Clec9aCre/CreRosaDTA mice 
arise independently of the classical CDP and pre-cDC differentia-
tion pathway.
cDc2 From Clec9aCre/CreRosaDTA Mice 
Phenotypically and Functionally resemble 
cDcs
Phenotypic analysis revealed that cDC2 from Clec9aCre/CreRosaDTA 
mice showed no alterations in surface expression of the cDC 
markers CD172a, MHCII, CLEC4A4, and ESAM, although the 
expression of CD4 was slightly lower on cDC2 from Clec9aCre/Cre 
RosaDTA mice compared to controls (Figure  4A). cDC2 from 
Clec9aCre/CreRosaDTA mice further showed normal expres-
sion of lineage defining transcription factors ZBTB46, IRF4 
and IRF8 (Figure  4A). cDC2 from control and Clec9aCre/Cre 
RosaDTA mice responded similarly to stimulation with the TLR 
ligands lipopolysaccharide (LPS) and CpG oligonucleotides 
(Figure 4B). Interestingly, upon LPS treatment fewer cDC2 from 
Clec9aCre/CreRosaDTA mice than from control mice produced TNF, 
whereas this was not the case for IL-12 (Figure  4B). Reduced 
TNF production after LPS stimulation was already present in 
cDC2 from young Clec9aCre/CreRosaDTA mice that did not yet 
display myeloproliferation (Figure 4C) indicating that it was not 
merely a functional adaptation to the myeloproliferative environ-
ment. We conclude that cDC2 from Clec9aCre/CreRosaDTA mice are 
broadly similar to cDC2 from control mice, other than a slight 
impairment in the production of TNF after LPS stimulation.
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FigUre 2 | Continued
FigUre 2 | Loss of cDC1 but not cDC2 in spleen from Clec9acre/creRosaDTA mice. (a–c) CD11c+MHCII+ conventional dendritic cells (cDCs) were identified by flow 
cytometry in spleen from Clec9acre/creRosaDTA and control mice and further analyzed for CD24 and CD11b expression, to identify cDC1 and cDC2, respectively. (a) 
Representative gating strategy to identify CD11c+MHCII+ cDCs, CD24+ cDC1, and CD11b+ cDC2. (B) Frequency and total counts of CD11c+MHCII+ cells in spleen 
from control and Clec9acre/creRosaDTA mice of the indicated ages. (c) Frequency and total counts of CD24+ cDC1 and CD11b+ cDC2 in mice of the indicated ages. 
(D,e) Clec9acre/creRosaDTR and control mice were injected i.p. with DT and 24 h later spleens were analyzed by flow cytometry to identify CD11c+MHCII+ cells, as well 
CD24+ cDC1 and CD11b+ cDC2 (D). (e) The frequency and counts of total cDCs and cDC subsets identified as in (D). Each symbol represents one mouse. ns, not 
significant; * p < 0.05, ** p < 0.001, and *** p < 0.0001.
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cDc2 From Clec9aCre/CreRosaDTA Mice are 
Transcriptionally similar to Bona Fide 
cDc2 but exhibit somatic 
rearrangements of lymphoid receptor 
genes
We next performed whole transcriptome profiling by microarray 
of cDC2 from Clec9aCre/CreRosaDTA mice. To this end, we sorted 
splenic CD11c+MHCII+CD11b+ cDC2 from Clec9aCre/CreRosaDTA 
mice (CD11b+ DTA) and compared their mRNA profile to that 
of cDC2 sorted as YFP+CD11c+MHCII+CD11b+ cells from 
Clec9aCre/CreRosaYFP mice (YFP+; Figure 5; Figure S3 and Table S1 
in Supplementary Material). We chose this experimental strategy 
to ensure comparison to bona fide cDC2 arising from Clec9a-
expressing myeloid cDC progenitors. Our analysis revealed 
surprisingly few differences in gene expression, indicating that 
cDC2 from Clec9aCre/CreRosaDTA mice are very similar to YFP+ 
cDC2. Interestingly, among the 50 most significantly differentially 
expressed genes, only 11 showed more than a twofold difference 
and we found CD135 as a top hit (Table S1 in Supplementary 
Material). The expression of CD135 was about twofold lower in 
cDC2 from Clec9aCre/CreRosaDTA mice than in YFP+ cDC2 (Table 
S1 in Supplementary Material), raising the possibility that expres-
sion of the lineage defining marker CD135 may be dysregulated at 
the mRNA level. Consistent with that notion, staining for CD135 
was reduced on cDC2 from Clec9aCre/CreRosaDTA mice (Figure 4A). 
However, incubation of cDCs with FLT3L inhibited CD135 stain-
ing intensity, even in conditions in which endocytosis should be 
blocked (Figure S3D in Supplementary Material), suggesting that, 
when occupied by FLT3L, CD135 may no longer be freely avail-
able for antibody binding. Therefore, decreased CD135 staining 
on cDC2 from Clec9aCre/CreRosaDTA mice may reflect the fact that 
the receptor is engaged by FLT3L, as well as a possible reduction 
in gene expression. We next used cDC and macrophage core 
gene signatures (65) and performed unsupervised hierarchical 
clustering of cDC2 from Clec9aCre/CreRosaDTA mice and YFP+ cDC2 
in the context of published datasets for cDC and macrophage 
populations from the Immgen database. When compared in this 
manner cDC2 from Clec9aCre/CreRosaDTA mice and YFP+ cDC2 
showed greater similarity to splenic cDC2 than to cDC1 or red 
pulp macrophages (Figures  5A,B; Figure S3 in Supplementary 
Material). cDC2 from Clec9aCre/CreRosaDTA mice did not display a 
migratory cDC signature (Figure S4 in Supplementary Material), 
suggesting that they are not cDC2 that have aberrantly migrated 
from the periphery.
We next performed principal component analysis (PCA) in 
the context of published datasets for splenic cDCs, thymic cDCs, 
migratory cDCs, splenic pDCs, macrophages, and monocytes. 
Notably, cDC2 from Clec9aCre/CreRosaDTA mice were most closely 
related to YFP+ cDC2 and splenic cDC2 and clustered far 
away from monocytes/macrophages, thymic cDCs, or pDCs 
(Figure 5C). In humans, a subset of cDC2 has been identified that 
appears to be related to pDCs (66). These cells can be distinguished 
from cDC2 and pDCs by expression of signature genes, including 
Axl, Pp1rb, Dab2, CD22, and IL3Ra (66). However, we found no 
enrichment of the Axl gene signature in cDC2 from Clec9aCre/Cre 
RosaDTA mice compared with YFP+ cDC2 (Figure  5D). Taken 
together, these data demonstrate that cDC2 from Clec9aCre/Cre 
RosaDTA mice do not show a comprehensive loss of cDC identity 
and resemble cDC2 from wild type mice.
CLPs can give rise to cDCs in vivo and in vitro under certain 
conditions (41–48) and pDCs in normal mice can originate 
from myeloid or lymphoid progenitors that appear phenotypi-
cally indistinguishable except for a history of RAG expression in 
those originating from the latter (50, 67–69). We therefore sorted 
CD11b+CD11c+MHCII+ cells from control and Clec9aCre/Cre 
RosaDTA mice (Figures  5E,F; Figures S5A–C in Supplementary 
Material) and performed PCR analysis for Ig gene rearrangements 
indicative of historical RAG activity. Sorted pDCs from control 
mice exhibited prominent Ig gene rearrangements (Figures 5E,F; 
Figure S5C in Supplementary Material), as reported (49, 50), 
serving as a positive control. Strikingly, cDC2 from Clec9aCre/Cre 
RosaDTA mice also showed clear evidence of Ig gene rearrange-
ments, which were completely absent in cDC2 from control 
mice (Figures 5E,F; Figure S5C in Supplementary Material). In 
summary, cDC2 that arise in the absence of Clec9a-expressing 
cDC progenitors are transcriptionally similar to bona fide cDC2 
but they exhibit RAG gene expression history in the form of D–J 
somatic rearrangements, indicating a putative lymphoid origin.
DiscUssiOn
Although the existence of a lymphoid path to cDC development in 
mice has been suggested (43, 47, 49, 50, 70), in steady-state cDCs 
arise primarily from myeloid progenitors (53). Here, we report 
the generation of Clec9aCre/CreRosaDTA mice as a model to consti-
tutively deplete Clec9a-expressing cDC progenitors and their 
progeny. We show that in the absence of these myeloid-derived 
cDC progenitors, cells that are phenotypically and transcription-
ally similar to bona fide cDC2 develop in spleen. These cells show 
RAG gene expression history in the form of D-J rearrangements 
at the IgH locus indicating a relation to the lymphoid branch of 
hematopoiesis. Therefore, our study suggests that lymphopoiesis 
can contribute to the generation of cDC-like cells in a situation in 
which myeloid cDC progenitors are impaired. This observation 
opens an interesting conundrum, namely, whether such cells 
FigUre 3 | Efficient depletion of conventional dendritic cell (cDC) progenitors in bone marrow and spleen. (a,B) cDC progenitors were identified by flow cytometry 
in the bone marrow of 10-week-old control and Clec9acre/creRosaDTA mice. (a) Live lineage negative (lin−; CD3, CD4, CD8, CD11b, MHCII, Ter119, NK1.1, and B220) 
cells were gated and further analyzed for CD11c, CD117, CD115, CD172a, and CD135 expression. Macrophage and DC progenitor (MDPs) were identified as 
CD11c−CD115+CD135+CD117hi cells, common DC progenitors (CDPs) as CD11c−CD115+CD135+CD117int/− cells, and pre-cDCs as CD11c+CD172aintCD135+ 
cells. (B) The number of MDP, CDP, and pre-cDC per femur is shown. (c) Lin−CD115+ CD117hi and lin−CD115+CD117int/− bone-marrow cells from control and 
Clec9acre/creRosaDTA mice were gated and further analyzed for CD135 expression. Mean fluorescence intensity (MFI) (n = 4) of the CD135+ cell fraction, as gated in 
the histogram overlays, is shown. It was normalized to MFI on the same population from control mice, which is set as 1. (D–F) Pre-cDCs in spleen from control and 
Clec9acre/creRosaDTA mice 10 weeks of age were identified as lin−CD11c+CD43+CD172aintCD135+ cells by flow cytometry (D). (e) The frequency and number of 
pre-cDCs per spleen is shown. (F) CD11c MFI on splenic lin−MCHII−CD11c+CD43+ cells from Clec9acre/creRosaDTA mice is shown. It was normalized to MFI on the 
same population from control mice, which is set as 1 (n = 4). Each symbol represents one mouse. ns, not significant; * p < 0.05, ** p < 0.001, and *** p < 0.0001.
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FigUre 4 | Continued
should be considered part of the cDC lineage. We and others have 
proposed that mononuclear phagocytes should predominantly 
be defined on the basis of their ontogeny (12, 71, 72). However, 
environmental imprinting appears to be a major identity deter-
mining criterion for mononuclear phagocytes (73–77). Therefore, 
an ontogenetic view to cell definition may be less tenable if cell 
FigUre 4 | cDC2 from Clec9aCre/CreRosaDTA mice phenotypically and functionally resemble cDCs. (a) Splenic CD11c+MHCII+CD11b+ cells from control (red) and 
Clec9acre/creRosaDTA (blue) mice were analyzed for the expression of indicated surface markers or transcription factors (lower line) by flow cytometry. Gray traces represent 
staining with isotype matched control antibody. (B,c) CD11c+ cells from control and Clec9acre/creRosaDTA mice of the indicated ages were enriched using magnetic 
beads, stimulated with lipopolysaccharide (LPS) (100 ng/mL) or CpG (0.5 µg/mL) for 6 h followed by intracellular cytokine staining. CD11c+MHCII+CD11b+ cDC2 were 
identified by flow cytometry and TNF and IL-12 production was analyzed. (B) The frequency of cytokine positive cDC2 is shown. (c) Frequency of TNF producing cDC2 
from mice of the indicated ages stimulated with LPS. Each data point represents one mouse. Data are compiled from two independent experiments. * p < 0.05.
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populations with different origins turn out to be identical by all 
measures examined. Because cDC2 in Clec9aCre/CreRosaDTA mice 
are not CDP-derived but show lymphoid gene expression history, 
we suggest to refer to these cells as lymphoid DC2 for the time 
being (12). Although we find strong similarities between cDC2 
and lymphoid DC2, additional studies are necessary to further 
define the transcriptional and growth factor requirements, as well 
as functional properties of lymphoid DC2 to firmly establish their 
lineage affiliation and determine whether these cells should be 
considered a new type of mononuclear phagocyte (12).
As cDC differentiation from precursors is thought to be 
homeostatically regulated by the size of the mature cDC pool 
(78, 79), we cannot formally exclude at this point that some 
CDPs escape deletion in Clec9aCre/CreRosaDTA mice to preferen-
tially expand and contribute to the cDC2 population. However, 
our data demonstrate that at least part of the cDC2 pool in 
Clec9aCre/CreRosaDTA mice derives from a cell type that has under-
gone Ig gene rearrangement and that pool is therefore qualitatively 
distinct from CDP-derived cDC2. Whether these ontogenetically 
distinct cDC2s arise from early lymphoid-committed progeni-
tors, such as CLPs, is an attractive possibility that will need to be 
explored. However, it is worth mentioning that some myeloid 
progenitors reportedly express RAG1 and can generate pDCs 
with D-J rearrangements in  vitro (50). Such RAG1-expressing 
myeloid progenitors, which would presumably lack DNGR-1, 
could contribute to cDC2 generation in Clec9aCre/CreRosaDTA mice, 
in which case our designation of these cells as “lymphoid cDC2” 
would be incorrect. Finally, it is possible that pDCs, some of 
which have a lymphoid past (49, 50), could convert to lymphoid 
cDC2 in the FLT3L-rich environment of Clec9aCre/CreRosaDTA mice, 
although this is difficult to reconcile with the fact that we failed 
to find any pDC-specific transcripts in lymphoid DC2 (Figure 5 
and unpublished observations). Another intriguing observation 
is that lymphoid DC2 display decreased surface staining for 
CD135. Gene expression analysis suggests that CD135 may be 
dysregulated at the RNA level (Figure 5). However, it is equally 
possible that CD135 could be downregulated upon continuous 
receptor engagement by FLT3L (80) or may no longer be available 
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FigUre 5 | cDC2 from Clec9aCre/CreRosaDTA mice are transcriptionally similar to bona fide cDC2 but exhibit somatic rearrangements of lymphoid receptor genes. 
Splenic CD11c+MHCII+CD11b+ cDC2 from Clec9acre/creRosaDTA mice (CD11b+ DTA) and CD11c+MHCII+CD11b+YFP+ cDC2 (YFP+) from Clec9acre/creRosaYFP mice 
were sorted and subjected to microarray analysis. (a,B) Population clustering and heat map display of the relative expression values for core conventional dendritic 
cells (cDC) signature genes (a) and core CD8neg cDC signature genes (B) comparing cDC2 from Clec9acre/creRosaDTA mice and YFP+ cDC2 to the indicated murine 
cDC and macrophage populations from the Immgen database. (c) Principle component analysis (PCA) was performed on 50% of the genes defined by highest 
variance across all samples. Each dot of the same color represents a replicate sample. For each cluster, normal confidence ellipses are indicated. (D) Box plots of 
the log2 expression values of the indicated genes in cDC2 from Clec9acre/creRosaDTA mice and YFP+ cDC2. (e,F) CD11c+MHCII+CD11b+ cDC2 from control and 
Clec9acre/creRosaDTA mice were sorted and genomic DNA was isolated. (e) Polymerase chain reaction (PCR) was performed using primers for the germline (GL) locus 
and primer mixtures homologous for regions of the Dfl16 and Dsp2 D gene families for detecting D–J rearrangements of the IgH chain. DJ rearrangements in pDCs 
(SiglecH+B220+) and neutrophils (Ly-6G+) are shown as control. * indicates an unspecific band. (F) Genomic PCR was performed using primers for the GL locus and 
primer sets for the DHQ52 element for detecting D–J rearrangements of the IgH chain. DJ rearrangements in pDCs (SiglecH+B220+), CD205+ cDC1, and neutrophils 
(Ly-6G+) are shown as control. Each lane in E and F represents independent replicates from different mice.
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